The use of liver grafts from donation after cardiac death (DCD) has been limited due to the increased rate of graft failure, mostly related to ischemic cholangiopathy (IC). It is our hypothesis that longterm outcomes and quality of life (QOL) similar to patients undergoing liver transplantation (LT) with donation after brain death (DBD) can be achieved. Clinical outcomes of all patients undergoing DCD LT (n 5 300) between 1998 and 2015 were compared with a propensity scorematched cohort of patients undergoing DBD LT (n 5 300). Patients were contacted for a follow-up questionnaire and short-form (SF)-12 QOL Survey administration. Median follow-up was >5 years. Graft survival at 1-, 3-, and 5-years was 83.8%, 75.5%, and 70.1% in the DCD LT group and 88.4%, 80.3%, and 73.9% in the DBD LT group (P 5 0.27). Patient survival at 1-, 3-, and 5-years was 92.3%, 86.1%, and 80.3% in the DCD LT group and 92.3%, 85.1%, and 79.5% in the DBD LT group (P 5 0.81). IC developed in 11.7% and 2% of patients in the DCD LT group and DBD LT group, respectively (P < 0.001). DCD LT recipients who developed IC had inferior graft survival compared with both the DCD non-IC group (P < 0.001) and the DBD LT group (P < 0.001); no difference in graft survival was observed between the DCD non-IC group and the DBD LT group (P 5 0.50). Physical and Mental Composite Scores on the SF-12 QOL questionnaire were similar between the DCD LT and DBD LT groups (44.0 versus 45.4; P 5 0.34 and 51.9 versus 52.2; P 5 0.83), respectively. Similar longterm survival and QOL scores can be achieved between DCD LT and DBD LT. Prevention of IC in DCD LT yields excellent graft and patient survival with virtually no difference compared with DBD LT.
Liver transplantation (LT) using donation after cardiac death (DCD) donors represents 1 potential approach to help address the rising discrepancy between the number of LT candidates and the availability of organs.
(1) Initial single-center and national reports examining the use of liver grafts from DCD donors described inferior longterm outcomes when compared with donation after brain death (DBD) donors. The inferior results were ascribed to high rates of biliary complications and increased rates of primary nonfunction (PNF) and hepatic artery thrombosis (HAT). (2) (3) (4) (5) (6) Ischemic cholangiopathy (IC) has previously been correlated with inferior patient and graft survival as well as reduced quality of life (QOL) through recurrent infections, need for repeat biliary interventions, and symptoms such as itching and fatigue. (4, 7) These initial reports resulted in reservations with the use of liver grafts from DCD donors; as a consequence the number of LTs using these organs did not increase as much as initially projected. (8) More recent publications reporting new surgical techniques and better patient Abbreviations: ACCT, asystole to cross-clamp time; BMI, body mass index; CIT, cold ischemia time; DBD, donation after brain death; DCD, donation after cardiac death; DRI, donor risk index; dWIT, donor warm ischemia time; ERCP, endoscopic retrograde cholangiopancreatography; HAT, hepatic artery thrombosis; HCC, hepatocellular carcinoma; IC, ischemic cholangiopathy; LT, liver transplantation; MCS, Mental Composite Score; MELD, Model for End-Stage Liver Disease; NA, not available; NASH, nonalcoholic steatohepatitis; PCS, Physical Composite Score; PNF, primary nonfunction; POD, postoperative day; PTC, percutaneous transhepatic cholangiogram; QOL, quality of life; SD, standard deviation; SF, short form.
selection have suggested that lower overall complication rates, such as IC, PNF, and HAT and higher survival rates can be achieved. (9) (10) (11) (12) The temporal differences in outcome highlight the need for more current and accurate data that can be applied in both statistical modeling and prospective decision making for the benefit of LT recipients and LT programs.
Although large registry-based studies provide an important overview of the use of liver grafts from DCD donors in the United States, their heterogeneity and lack of detailed longterm follow-up leave many questions unanswered. (13) In addition, longterm follow-up data concerning DCD liver graft recipients are critical to examine the morbidity and QOL in these patients. Since the inception of the LT program at Mayo Clinic Florida in 1998, DCD donors have been used in a consistent and considered manner to meet the demand for liver grafts. The present study aims to provide detailed and complete longterm analysis and QOL in recipients of DCD LT grafts as the largest single-institution analysis to date. It is our hypothesis that similar longterm outcomes and QOL can be achieved in recipients of DCD liver grafts compared with patients undergoing LT with liver grafts from DBD donors.
Patients and Methods
This study was performed with the approval of the Mayo Clinic institutional review board. Data were acquired from patients' medical records, outside medical records, and from a prospectively maintained transplant database on all patients who underwent LT at our program. QOL data were acquired from a written survey mailed to all recipients of DCD LT and matched recipients of DBD LT grafts who were known to be alive.
All patients undergoing LT at Mayo Clinic Florida between the dates of February 28, 1998 and April 30, 2015 were identified. A 1:1 propensity match between patients undergoing DCD LT and DBD LT was performed matching for the following variables: recipient age, sex, body mass index (BMI), liver disease etiology, biological Model for End-Stage Liver Disease (MELD) score at transplant, match MELD at transplant, secondary diagnosis of hepatocellular carcinoma (HCC), retransplantation status, and calendar year of transplantation. Matching on recipient factors was meant to create a matched comparison of LT candidates on the waiting list that would have been listed for a liver graft either from a DBD or DCD donor. A multivariate logistic regression model predicting the probability of receiving a DCD liver was performed, and propensity scores were created. Patients were matched 1:1 without replacement. Caliper matching on propensity score was performed. Propensity score matching was performed using Stata "psmatch" functions. Graphic verification was used to check that covariates were balanced across treatment and comparison groups. In this matching method, a variable that strongly predicts the likelihood of receiving a DCD liver graft (in our sample MELD or retransplant status) would by nature of the prediction model have a larger weight, whereas weaker predictors such as BMI would have less weight. This method indirectly gives more "priority" to certain variables. Finally, a sensitivity analysis matching on both the aforementioned recipient factors and donor risk index (DRI) was performed.
The primary outcome measures were graft and patient survival, post-LT biliary and vascular complications, and QOL scores. Graft survival was calculated from the time of LT until death, graft loss, or date of last follow-up. Patient survival was calculated from the date of LT to death or last-known follow-up. For DCD donors, donor warm ischemia time (dWIT) was defined as the time from withdrawal of both ventilator and cardiac support to the time of aortic cross-clamping. (14) DRI for each liver graft was calculated using the previously published formula. (15) The techniques of organ retrieval and LT at our center have previously been described in detail. (12, 14, 16) Thrombolytic agents were not used in any of the grafts during organ procurement or at the time of LT. Ductto-duct biliary reconstruction with transcystic biliary tube was used in both DCD and DBD graft recipients except in patients with primary sclerosing cholangitis or when deemed unfeasible by the recipient surgeon. Protocol cholangiograms through the biliary catheter were performed on postoperative day (POD) 3 and POD 21 on patients with biliary catheters. (17) If no abnormalities were identified, the biliary catheter was then removed. Cholangiograms were performed prior to POD 21 if clinically indicated. All intrahepatic and extrahepatic strictures were documented even if not clinically significant at the time of cholangiogram. Strictures were classified according to previously described systems as localized (anastomotic or nonanastomotic) or diffuse IC. (18) IC was defined as diffuse, intrahepatic bile duct strictures, in the absence of HAT. IC is diagnosed with either cholangiogram using an intraoperatively placed transcystic duct biliary tube, by endoscopic retrograde cholangiopancreatography (ERCP) or by percutaneous transhepatic cholangiogram (PTC).
All surviving LT recipients in the study and matched groups were contacted for a follow-up questionnaire and short form (SF)-12 QOL Health Survey administration. Patients who did not reside in North America were excluded. SF-12 is a multipurpose generic QOL instrument derived from the SF-36 Health Survey. (19, 20) The SF-12 has been previously validated in a study of patients who have undergone LT. (21) For the SF-12 analysis, mean values for the Physical Composite Score (PCS) and Mental Composite Score (MCS) were compared with the propensity-matched group of patients undergoing LT with a DBD graft as well as with that of the general population (mean 6 standard deviation [SD], 50 6 10). Pruritus was measured from 0 to 10 by a previously validated visual analogue scale. (22) All statistical analyses were performed using STATA 12 software (StataCorp., College Station, TX). Results were presented as mean 6 SD except in situations where results were not normally distributed in which case they were presented as median (range). Differences between groups were analyzed using the unpaired t test for continuous variables and by the v (2) test or continuity correction method for categorical variables. Wilcoxon rank sum was used for variables that did not display a normal distribution. Survival curves for patient or graft survival were generated using the Kaplan-Meier method and compared by the logrank test. All statistical tests were 2-sided, and differences were considered significant when P < 0.05.
Results
During the study period, a total of 300 DCD LTs and 2512 DBD LTs were performed at our program. Follow-up of at least 1 year was complete in all patients included in the study. Recipient characteristics for the 2 groups can be seen in Table 1 . Given that patients were matched based on recipient characteristics, no significant differences were seen between the groups. Donor and graft characteristics for the 2 groups can be seen in Table 2 . DCD donors were younger than DBD donors (mean age, 38.9 6 15.4 versus 46.2 6 17.5 years; P < 0.001), had a shorter cold ischemia time (CIT; 5.9 6 1.4 versus 6.8 6 2.0 hours; P < 0.001), were more likely to be Caucasian (88% versus 69%; P < 0.001), were less likely to have died from stroke (22% versus 53%; P < 0.001), more likely to have died from anoxia (27% versus 16%; P 5 0.002) or trauma (48% versus 29%; P < 0.001), and were less likely to be regional (36% versus 44%; P 5 0.03) or national shares (7% versus 23%; P < 0.001). In the DCD LT, median dWIT was 23 minutes (range, 4-59 NOTE: Data are presented as n (%) or as mean 6 SD (with medians and ranges in parentheses).
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minutes). Asystole to cross-clamp time (ACCT) in DCD donors was 8.9 6 4.0 minutes (range, 3-14 minutes). Mean time on the waiting list prior to LT was 105 6 165 days in the DCD LT group and 117 6 259 days in the DBD LT group (P 5 0.52). Mean operative time during LT was 262 6 91 minutes in the DCD LT group and 262 6 85 minutes in the DBD LT group (P 5 0.95).
Postoperative biliary and vascular outcomes for the 2 groups can be seen in Table 3 . Rates of HAT (2.3% versus 2%; P 5 0.78) and vascular stenosis (4.3% versus 5.3%; P 5 0.57) were not significantly different between the DCD LT and DBD LT groups, respectively. The total number of biliary complications was 81 (27%) in the DCD LT group and 53 (17.7%) in the DBD LT group (P 5 0.006). Both IC (11.7% versus 2%; P < 0.001) and biliary leaks (11.7% versus 6.3%; P 5 0.02) were significantly higher in the DCD LT compared with the DBD LT group. No difference in localized strictures, be it anastomotic (9% versus 9%; P > 0.99) or nonanastomotic (2.7% versus 3.7%; P 5 0.48), was seen between the study groups.
A total of 35 (11.7%) patients receiving DCD LT developed IC. A total of 22 (63%) of the 35 patients who developed IC were ultimately listed for re-LT. The median time from initial DCD LT to listing for re-LT was 69 days (range, 4-286 days), whereas the median time from listing until re-LT was 124.5 days (range, 4-1374 days).
The median follow-up was 73 months in the DCD group and 62 months in the DBD group. Patient survival was similar between the DCD LT and DBD LT groups (P 5 0.81): patient survival at 1-, 3-, and 5-years was 92.3%, 86.1%, and 80.3% in the DCD LT group and 92.3%, 85.1%, and 79.5% in the DBD LT group (Fig. 1) . Although a slight trend of inferior graft survival was observed in the DCD LT group compared with the DBD LT group, this was not statistically significant (P 5 0.27): graft survival at 1-, 3-, and 5-years was 86.1%, 78.4%, and 73.2% in the DCD LT group and 89.3%, 82.2%, and 77.1% in the DBD LT group (Fig. 2) . NOTE: Data are presented as n (%) or as mean 6 SD (with medians and ranges in parentheses). In subanalysis, graft survival was compared between DCD LT recipients who developed IC, DCD LT recipients who did not develop IC, and the propensitymatched cohort of DBD LT recipients: DCD LT recipients who developed IC had inferior graft survival compared with both the DCD non-IC group (P < 0.001) and the DBD LT group (P < 0.001). No difference in graft survival was seen between the DCD non-IC group and the DBD LT group (P 5 0.50; Fig.  3 ). Graft survival at 1, 3, and 5 years was 59.4%, 37.4%, and 27.2% in the DCD IC group; 89.2%, 83.3%, and 78.8% in the DCD non-IC group; and 89.3%, 82.2%, and 77.1% in the DBD LT group.
A sensitivity analysis comparing DCD and DBD outcomes matching on both recipient factors and donor DRI was performed. In this match, there was no difference in DRI between the 2 groups (DCD 1.92 6 0.47 versus DBD 1.90 6 0.47; P 5 0.73). DRI-matched DBD donors had a higher proportion of donor age > 70 years (DCD 0.7% versus DBD 27%; P < 0.001) and a higher proportion of national share offers (DCD 7% versus DBD 35%; P < 0.001). No difference in patient (P 5 0.86) or graft survival (P 5 0.64) was seen when comparing these recipient and donor DRI-matched groups.
DCD SUBGROUP ANALYSIS BY ERA
DCD LTs were divided into the first 100 DCDs performed (February 28, 1998 to August 5, 2006), the second 100 DCDs performed (August 6, 2006 to January 14, 2010), and the third 100 DCDs performed (January 15, 2010 to April 30, 2015) . Graft survival was not statistically significant between era 1 and era 2 (P 5 0.32) but was significantly improved between era 2 and era 3 (P 5 0.038) and between era 1 and era 3 (P 5 0.003; Fig. 4) . The number of patients developing IC was lower in era 3 (n 5 4) compared with era 2 (n 5 17; P 5 0.003) and era 1 (n 5 14; P 5 0.01). 
QOL SURVEY RESULTS
Surveys were mailed to a total of 360 patients (DCD LT and propensity-matched DBD LT cohort). The survey was completed by 236 patients (66% response rate). Response rate was 72% (143/200) for recipients of DCD LT and 58% (93/160) for recipients of DBD LT. The median follow-up in those who completed the survey was 7.1 years (range, 9 months to 16 years) in the DCD LT group and 5.5 years (range, 8 months to 17 years) in the DBD LT group. Results of the survey can be seen in Table 4 .
On the SF-12 questionnaire, mean PCS was not statistically different between the DCD LT (44.0 6 11.1) and DBD LT (45.4 6 11.6) groups (P 5 0.34). The PCS score was lower than the general US population (50 6 10) in both groups (P < 0.001 for both comparisons). Mean MCS was also not statistically different between the DCD LT (51.9 6 9.2) and DBD LT (52.2 6 10.4) groups (P 5 0.83). The MCS score was higher than the general US population (50 6 10) for both the DCD LT group (P 5 0.01) and for the DBD LT group (P 5 0.04). In the DCD LT group, 37% of patients were described as having pruritus compared with 28% of patients in the DBD LT group (P 5 0.016). There was no difference in the severity of pruritus for a score of 1-5 (P 5 0.18) or 6-10 (P 5 0.72) between the 2 groups. There was also no significant difference in the proportion of patients who required invasive biliary intervention > 6 months after their LT (18% versus 17%; P 5 0.82) or in the number of patients who required antibiotics for biliary-related infection (13% versus 10%; P 5 0.40) in the DCD LT and DBD LT groups, respectively. In the DCD LT group, 38% of patients returned to work following their LT compared with 37% of patients in the DBD LT group (P 5 0.77). There was no difference in the percentage of people who did not return to work (17% versus 17%; P 5 0.93) or in the percentage of people who were retired or did not work prior to LT (45% versus 46%; P 5 0.82) in the DCD LT and DBD LT groups, respectively. At the time of the survey, 23% of patients in the DCD LT group and 29% of patients in the DBD LT group reported that they were working (P 5 0.30). For those patients who were not working at the time of the survey, there was no difference in the reason between the DCD LT and DBD LT groups.
Discussion
Because of the inferior results associated with DCD LT in many published reports, there is continuing reluctance among centers to use DCD liver grafts. (4, 23) This reluctance is based on retrospective reports from either registry data which are fraught with mixed experiences, limited specifics, and lack of detailed longterm follow-up, or single-center experiences which are limited by size and institutional bias. As recently as 2016, a multicenter European consortium suggested worse graft survival with DCD LT, (24) and yet no randomized controlled trial has been or likely will ever be performed to investigate the comparison of outcomes for recipients of DCD LT versus DBD LT. Recognizing the limitations of a retrospective data set, we sought to use propensity score matching to simulate the benefits of a randomized controlled trial, whose goal is to minimize confounding bias. (25, 26) In this study, we performed propensity matching of recipient characteristics alone (recipient age, sex, BMI, liver disease etiology, biological MELD score at transplant, match MELD at transplant, secondary diagnosis of HCC, retransplantation status, and calendar year of transplantation) with the goal of designing a study to compare outcomes for recipients of DCD LT versus DBD LT. In doing so, we were attempting to create a matched comparison of LT candidates on the waiting list who could have hypothetically received either a liver graft from a DCD or a DBD donor, because we do not list all patients for a DCD LT. This analysis could potentially be useful to determine whether or not to accept a DCD liver graft at the time of organ offer. In a recently published study with propensity matching using donor characteristics, Laing et al. matched 187 of 234 DCD grafts implanted over a 10-year period with DBD graft recipients: similar graft and patient survival were demonstrated between DCD LT and DBD LT. (27) In the current study, we performed a propensity match on all recipients of DCD grafts using recipient characteristics to mimic randomization as much as possible, thereby permitting comparison between the 2 groups. We would argue that matching solely on donor characteristics is in fact counterproductive. By matching on recipient factors, patients receiving a DCD graft would be compared with the outcomes of the DBD grafts a similar recipient on the transplant list would have received. Similarly, when we performed a sensitivity analysis matching on both recipient factors and DRI, no difference in graft or patient survival was seen between the DCD and DBD groups. Herein, we demonstrated that patient survival was similar between the DCD LT and DBD LT groups. Although a slight trend of inferior graft survival was seen in the DCD LT group compared with the DBD LT group, this was not statistically significant. QOL scores for patients who received either a DCD or DBD liver graft did not differ as measured by either MCS or PCS scores. Among complications, the only statistically significant difference between the 2 groups was related to biliary complications. The rate of overall biliary complications was significantly higher in the DCD (27.0%) compared with the DBD (17.7%) group. Rates in both groups were lower than in some earlier reports, (23) likely representing improvements over time with increased experience by the transplant community at large. The overall rate of IC was 12% in the DCD group compared with 2% in the DBD group. In a subanalysis, we found that DCD LT patients who developed IC had inferior graft survival compared with both the DCD non-IC group (P < 0.001) and the propensity-matched cohort of DBD LT recipients (P < 0.001); no difference in graft survival was seen between the DCD non-IC group and the DBD LT group (P 5 0.50). These data highlight the fact that IC is the leading cause of graft loss in DCD LT. Focusing on strategies to prevent the development of IC remains vital to the widespread use of this type of graft. IC represents irreversible damage to bile ducts, with a spectrum of disease characterized by multiple diffuse intrahepatic strictures in the absence of HAT. (4, (27) (28) (29) (30) Clinical manifestations of IC are usually evident between 1 and 3 months after LT when there is involvement of both intrahepatic and extrahepatic bile ducts. (31) We have observed that IC has a severity and geographic spectrum; not all cases of IC are severe enough to require retransplantation. (16) To the best of our knowledge, the QOL data (with a 72% survey response rate) presented in this report represents the largest such data in DCD liver graft recipients. The data include measurable metrics reported by patients to document mental and physical condition. QOL data are valuable as an important complimentary documentation of outcomes. We did not observe a difference in longterm QOL between recipients of DCD LT and DBD LT. These results are in contrast to a previous QOL analysis that found inferior QOL in a cohort of 30 patients undergoing DCD LT. (32) In that study, the mean MCS was 38.4 for DCD LT recipients who did not develop IC, 30.7 for patients who developed IC, and 44.3 for DBD LT recipients. We found that the MCS score was similar between DCD LT and DBD LT recipients, and these values were similar to the DBD cohort in the aforementioned study. MCS was also significantly higher for both DCD LT and DBD LT groups in this report. These differences in QOL scores between the 2 studies may be related to differences in rates of IC and graft failure. Importantly, compared with the QOL scores of patients suffering with end-stage liver disease (previously reported as a mean MCS of 41 and PCS of 30.8), we observed a marked improvement in scores after LT for both recipients of DCD or DBD liver grafts. (33) 
LESSONS LEARNED OVER 300 DCD LTS
There is no question that there has been a learning curve both within our own program and nationally over time. (34) We have seen a reduction in our rate of IC from 16% in the first 200 DCD LTs to 4% in the last 100 DCD LTs in this study. This improvement is likely multifactorial, resulting from changes in both recipient and donor selection. From a donor standpoint, we are very strict on the importance of ACCT and try to keep this time under 10 minutes. Previous authors have emphasized the importance of reducing dWIT. (2, 12, 35) Using a more nuanced breakdown of dWIT, we previously identified ACCT as a significant predictor of IC and biliary complications. (12, 14) We noticed a large reduction in the rate of IC in era 3 of the present analysis when we started placing emphasis on ACCT time. Efforts to shorten ACCT should be considered by transplant programs as well as organ procurement organizations because events during DCD liver graft procurement are linked to the development of IC. In addition, we only use DCD liver grafts that have been procured by an attending surgeon from our team. This ensures consistency of procurement technique, minimizes ACCT, and allows experienced assessment of organ quality. We also target a CIT of <6 hours. We have extended donor age cutoff to 65 years, as we have observed little correlation with donor age in our cohort.
We have made a number of adjustments in identifying recipients suitable for DCD LT based on our group's experience: we no longer list certain patients for DCD liver grafts. Our practice changed over the 3 eras from listing the majority of patients for DCD LT to excluding certain patients from DCD listing: this is due to inferior results which have become more apparent based on our previous analyses. These exclusion criteria include critically ill patients in the intensive care unit, re-LT cases, and patients with hepatopulmonary syndrome. In addition, patients requiring simultaneous liver and kidney transplantation constitute a relative contraindication due to the reported inferior single-center and national results. (36) (37) (38) Patients with low biological MELD score, such as patients with secondary diagnosis of HCC, may represent ideal candidates for DCD LT due to their potentially more straightforward hepatectomy and less complicated intraoperative course. We have previously shown that there was no difference in HCC recurrence or survival between DCD LT and DBD LT recipients. (39) The increased and successful use of DCD LT in the patients with HCC in regions transplanting at higher MELD scores could potentially help alleviate some of the organ shortage in these regions, while still maintaining acceptable posttransplant results and decreasing wait-list mortality.
Limitations of the QOL assessment in this study include measurement at a single but variable time period after LT without continuous (multipoint) measurements. In addition, patients who were deceased did not receive the survey. Conceptually, there could also be sampling error due to the voluntary nature of participation in the questionnaire. Other limitations of this analysis are that because we matched on recipient characteristic, donors in the control group (DBD) differed from the treatment (DCD) group. We tried to create a matching scenario for someone on the waiting list for the potential organ offers they would be receiving (therefore the match is based on recipient and not donor variables). The equivalent results between DCD and DBD in the present study should not be interpreted as there is no difference between the "ideal" DBD donor and a DCD donor. Instead our results should be interpreted that the use of a DCD graft yields equivalent results to the DBD grafts a similar patient on the waiting list would have access to. In addition and equally important to posttransplant outcomes, successful utilization of DCD liver grafts may potentially prevent wait-list mortality.
In conclusion, in a large cohort of patients who received DCD LT grafts, we report that longterm outcomes and QOL were comparable to a propensitymatched group of DBD LT patients. The data and analyses presented also highlight the importance of preventing IC in order to achieve acceptable outcomes. Systematic and successful utilization of DCD donors, incorporating the lessons learned over time may increase access to LT and reduce wait-list mortality while providing satisfactory outcomes in select recipients who may not otherwise have access to the "ideal" DBD liver graft.
